ERBB2 and breast cancer: This vaccine stimulated better CD4-positive T-cell responses, leading to a higher induction of HER2-specific antibodies (~70 μg/mL) than the former vaccine (~40 μg/mL), suggesting that this vaccine may be a new therapeutic alternative for patients with trastuzumab-resistant HER2-positive BC.